(Q40212794)

18 September 2017

A clinical trial of topically applied 3 percent vidarabine against recurrent herpes labialis (English)

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

2 June 2022

author name string

Shipman C Jr

8

1 reference

18 September 2017

N. H. Rowe

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A218154

2 June 2022

S. L. Brooks

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A218154

2 June 2022

S. K. Young

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A218154

2 June 2022

J. Spencer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A218154

2 June 2022

T. J. Petrick

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A218154

2 June 2022

R. A. Buchanan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A218154

2 June 2022

J. C. Drach

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A218154

2 June 2022

C. Shipman

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A218154

2 June 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=218154

2 June 2022

publication date

1 February 1979

1 reference

full work available at URL

18 September 2017

https://api.elsevier.com/content/article/PII:0030422079901695?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

https://api.elsevier.com/content/article/PII:0030422079901695?httpAccept=text/plain

2 June 2022

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

Oral surgery, oral medicine, and oral pathology

2 June 2022

published in

1 reference

18 September 2017

47

1 reference

18 September 2017

2

1 reference

18 September 2017

142-147

1 reference

18 September 2017

Herpes simplex keratitis

2

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

Treatment of Zoster with Idoxuridine in Dimethyl Sulphoxide. Results of Two Double-blind Controlled Trials

2 June 2022

3

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

Failure of high dose 5-iodo-2'-deoxyuridine in the therapy of herpes simplex virus encephalitis. Evidence of unacceptable toxicity

2 June 2022

4

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

Absence of Idoxuridine and Persistence of Herpes Simplex Virus In Brains of Patients Being Treated for Encephalitis

2 June 2022

5

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

Herpes Zoster Ophthalmicus Treated With Cytarabine

2 June 2022

6

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

Clinical evaluation of adenine arabinoside and trifluorothymidine in the treatment of corneal ulcers caused by herpes simplex virus

2 June 2022

8

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

Ineffectiveness of Subcutaneous Cytosine Arabinoside in Localized Herpes Zoster

2 June 2022

0 references

Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial

10

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

Is cytarabine an effective drug against herpes zoster? (author's transl)

2 June 2022

11

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

The selective inhibition of viral DNA synthesis by chemotherapeutic agents: an indicator of clinical usefulness?

2 June 2022

16

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study

2 June 2022

18

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

A clinical study for the control of facial mucocutaneous herpes virus infections. I. Characterization of natural history in a professional school population

2 June 2022

20

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

Herpes Simplex Virus Types 1 and 2 in Clinical Infections: Differences Observed by Electron Microscopy

2 June 2022

22

1 reference

https://api.crossref.org/works/10.1016/0030-4220(79)90169-5

2 June 2022

Identifiers

1 reference

18 September 2017

1 reference